$0.02
15.24%
Nasdaq, Fri, Sep 27 2024
ISIN
CA91822J1030
Symbol
VBIV
Sector
Industry

VBI Vaccines, Inc. Stock price

$0.02
-0.00 1.11% 1M
-3.25 99.46% 6M
-3.25 99.46% YTD
-3.25 99.46% 1Y
-102.28 99.98% 3Y
-14.80 99.88% 5Y
-250.78 99.99% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.00 15.24%
ISIN
CA91822J1030
Symbol
VBIV
Sector
Industry

Key metrics

Market capitalization $600.00k
Enterprise Value $38.71m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.11
P/S ratio (TTM) P/S ratio 0.06
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 553.09%
Revenue (TTM) Revenue $9.41m
EBIT (operating result TTM) EBIT $-47.56m
Free Cash Flow (TTM) Free Cash Flow $-50.92m
Cash position $12.60m
EPS (TTM) EPS $-6.93
P/E forward negative
P/S forward 1.23
EV/Sales forward 4.16
Short interest 1.16%
Show more

Is VBI Vaccines, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

VBI Vaccines, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast VBI Vaccines, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast VBI Vaccines, Inc.:

Buy
100%

Financial data from VBI Vaccines, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '24
+/-
%
9.41 9.41
553% 553%
100%
- Direct Costs 14 14
4% 4%
149%
-4.56 -4.56
65% 65%
-48%
- Selling and Administrative Expenses 32 32
40% 40%
339%
- Research and Development Expense 8.76 8.76
46% 46%
93%
-45 -45
45% 45%
-481%
- Depreciation and Amortization 2.30 2.30
5% 5%
24%
EBIT (Operating Income) EBIT -48 -48
44% 44%
-505%
Net Profit -83 -83
31% 31%
-882%

In millions USD.

Don't miss a Thing! We will send you all news about VBI Vaccines, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

VBI Vaccines, Inc. Stock News

Neutral
InvestorPlace
about 2 months ago
VBI Vaccines (NASDAQ: VBIV ) stock is rising higher on Tuesday after the commercial-stage biopharmaceutical company filed for bankruptcy last week. According to a press release from VBI Vaccines, this bankruptcy filing is part of the company's ongoing restructuring effort.
Neutral
Business Wire
about 2 months ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided an update on the restructuring proceedings announced on July 30, 2024. U.S. Chapter 15 Filing On August 2, 2024, the United States Bankruptcy Court for the District of Delaware granted provision...
Neutral
Business Wire
3 months ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 25, 2024 (the "Meeting"). The total number of common shares of the Company ("Common Shares") r...
More VBI Vaccines, Inc. News

Company Profile

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.

Head office United States
CEO Jeff Baxter
Employees 138
Founded 1965
Website www.vbivaccines.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today